Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints, which may lead to joint damage, deformity, and disability, if not managed effectively [1, 2] . Many anti-arthritic drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) are available [3] [4] [5] [6] [7] , but frequently their prolonged use is accompanied by severe adverse effects. Furthermore, about 40% of patients fail to respond to biologics (e.g., anti-tumor necrosis factor-α (TNF-α) and anti-interleukin-6 receptor (IL-6R) antibodies) [8, 9] , and patients treated with those drugs are at risk of severe infections [7, 10] . The above-mentioned drugs are given to RA patients either orally or by systemic injection. Accordingly, in the process of achieving an effective local dose of the drug at the target site (the inflamed joint), several other organs are inadvertently exposed to these drugs, resulting in damage to the liver or kidney, for example. Furthermore, many of these drugs are not meant for use by local intraarticular injection. Thus, efficient and safe delivery of drugs is a desired goal for the management of RA.
We reasoned that targeted delivery of systemically administered anti-arthritic drugs preferentially into the inflamed joints might help overcome some of the above-mentioned limitations of the anti-arthritic T drugs and thereby, improve their therapeutic index. Drug delivery vehicles belong to two main categories, viral and non-viral. In general, the biosafety profiles of non-viral vectors such as liposomes, polymers and dendrimers are better than that of viral vectors. Liposomes are wellstudied vehicles for encapsulating drugs and other biomolecules for therapeutic purposes [11, 12] . Most of the previous studies on liposomal drug delivery are based on plain liposomes that lack a specific ligand to direct them to the desired target site. However, a series of studies by Ruoslahti and colleagues [13] [14] [15] and others [16, 17] have described targeted delivery of the entrapped drugs to the tumor site using liposomes whose surface was modified with a tumor-homing peptide [13, [16] [17] [18] . In addition, these liposomes were conjugated with polyethylene glycol (PEG) to reduce their uptake by the reticuloendothelial system and thereby, preventing rapid elimination from systemic circulation. Similar attempts using a peptide or other ligands are being made for the targeted delivery of drugs in autoimmune diseases, including RA [19] [20] [21] [22] and systemic lupus erythematosus (SLE, lupus) [23] .
In this study, we set out to develop and test a peptide-directed liposomal drug delivery system in arthritic rats for inhibiting the progression of the disease. In a previous study, we have reported the identification of a 9-amino acid peptide ligand ADK ((henceforth denoted as ART-1) that preferentially homed to inflamed joints of arthritic rats [24] . This peptide was identified using ex vivo and in vivo screening of a phage peptide-display library. It showed binding to the vascular endothelium in sections of inflamed joint tissue as well as to joint-derived rat endothelial cells and cultured (activated) human endothelial cells in vitro. We selected peptide ART-1 for targeting a systemically administered immunomodulatory cytokine (IL-27) into the joints of arthritic rats. IL-27 is a new member of the IL-12 family and it consists of the Epstein-Barr virus-induced gene 3 (EBI3) and p28 subunits [25] [26] [27] . In an earlier study, we have shown that the treatment of arthritic rats with IL-27 inhibited the development and progression of arthritis [28] . The beneficial effect of IL-27 was attributable in part to the inhibition of IL-17 response. The immunomodulatory activity of IL-27 in arthritic rats was further validated by subsequent reports in a mouse model of arthritis by other investigators [29] .
We hypothesized that surface conjugation of IL-27-encapsulating liposomes with peptide ART-1 would help route them preferentially into the inflamed arthritic joints, and thereby, enhance the efficacy but reduce any adverse effects of treatment compared with free IL-27. The results described below support this proposition. We believe that with appropriate modifications, this peptide-directed drug delivery approach can be adapted for RA therapy with IL-27 or another drug of interest.
Materials and methods
IL-27 was purchased from PeproTech, USA. DOPC (1, 2-Dioleoyl-snglycero-3-phosphocholine), DOPE (1, 2-Dioleoyl-sn-glycero-3-phosphoethanolamine), cholesterol and FITC (fluorescein isothiocyanate) were obtained from Sigma-Aldrich, USA. DSPE-PEG (2000) amine (1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000] (ammonium salt)) was purchased from Avanti Polar Lipids, USA. Cyanine 7 azide (Cy7) was purchased from Lumiprobe, USA. ART-1-lipopeptide (CRNADKFPC-NH-C 18 H 37 ) was custom-synthesized by GenScript/Lifetein, USA. The structure of ART-1-lipopeptide is shown in Fig. S1 . The peptide in both the lipopeptide and liposomal formulation used in this study was found to be in cyclic form (CeC disulfide 1-9) as assessed by LC-MS spectra of ART-1-lipopeptide: m/z calculated 1301.74 for CRNADKFPC-NH-C 18 
Preparation of liposomes

FITC-/Cy7-containing liposomes
The lipids DOPC, DOPE, cholesterol, and DSPE-(PEG) 45 -NH 2, and a fluorescent dye (FITC/Cy7) were dissolved in chloroform/methanol in a molar ratio (1: 0.5: 0.5: 0.01: 0.05) in a glass vial. This composition was based on a study by Barui et al. [30] but further optimized for our preparation to obtain good stability and entrapment efficiency, but no aggregation of liposomes. The solvent was removed with a thin flow of moisture-free nitrogen gas. For preparing liposomes displaying the ART-1 peptide on their surface, the ART-1-lipopeptide was added (at 1 M ratio relative to above-mentioned molar ratio for different lipids) to the lipids, but for control liposomes, only the lipids were used. One mL of sterile deionized water or phosphate-buffered saline (PBS) was added to the dried lipid film and the mixture was allowed to swell overnight at room temperature. The vial was then vortexed for 3 min at room temperature to produce multilamellar vesicles (MLVs). MLVs were then sonicated, initially using an Ultrasonic water bath (CPX series, Branson Ultrasonics, CT, USA) followed by probe sonifier (Fisher Scientific) at 100% duty cycle and 25 W output power, to produce small unilamellar vesicles (SUVs). These liposomes containing FITC/Cy7 were then centrifuged using Amicon ultra-4 centrifugal filter units (10 kDa) for 20 min at 5000 rpm to remove un-encapsulated FITC/Cy7. A similar procedure was followed for preparing ART-1-containing liposomes but without any fluorescent dye (ART-1 liposomes).
IL-27-containing liposomes
For liposomal entrapment of IL-27, the dried lipid film prepared using above-mentioned lipids in the indicated molar ratio was hydrated with 1 ml PBS containing IL-27 (10 μg), and the mixture was allowed to swell overnight at 4°C. The vial was then vortexed for 3 min at room temperature to produce MLVs and then SUVs as described above. The resulting liposomes were then centrifuged for 60 min at 60,000 rpm at 4°C using a Beckman L8-80 M ultracentrifuge to remove un-encapsulated IL-27. The supernatant was removed and the pellet was hydrated with PBS [31] . Depending on the presence or absence of the ART-1-lipopeptide, the end product was ART-1-IL-27 liposome or control-IL-27 liposome, respectively. Above-mentioned ART-1 liposomes, which displayed ART-1 but lacked any entrapped test agent (in this case IL-27), served as an additional control for ART-1-IL-27 liposomes in the experiments described below.
Physical characteristics of liposomes
Measurement of zeta size and zeta potential
The zeta size and zeta potential of liposomes containing FITC, Cy7 or IL-27 were measured using a Zetasizer (Malvern Zetasizer Nano). The size measurement was done in deionized water (1 ml) with a sample (50 μl) refractive index of 1.59 and a viscosity of 0.89. Dynamic light scattering (DLS) was used to measure particle size of liposomes. Samples were diluted 1 in 5 with deionized water and zeta potential was measured using the following parameters: viscosity, 0.89 cP; dielectric constant, 79; and temperature, 25°C. All the size measurements were done 10 times in triplicate with the zero field correction, and values represented as the average of triplicate measurements. The zeta potential was measured 10 times and represented as an average value, as calculated by using the Smoluchowski approximation [32] .
Transmission electron microscope (TEM) images
Five microliters of IL-27-liposomes were placed on a 200-mesh copper grid and allowed to adsorb. The surplus sample was removed by a filter paper. Five μL of 2% (w/v) aqueous solution of uranyl acetate were added and left in contact with the sample for 5 min. The surplus water was removed and the sample was dried under room conditions. The liposomes were imaged with a Transmission electron microscope FEI tecnai T12 operating at an acceleration voltage of 80 KV [33] .
Determination of liposomal loading efficiency for IL-27 by HPLC
The entrapment efficiency (EE) of IL-27 in the liposomes was quantified by the indirect method using RP-HPLC and UV detection. The analytical system consisted of a Waters Alliance 2695 HPLC and a 2996 photodiode array detector coupled to a Waters Symmetry C4 reversed phase column (2.1 mm × 150 mm). Absorbance was monitored at 215 nm. The solvents consisted of 0.1% trifluoroacetic acid (TFA) in water (A) and 0.1% TFA in acetonitrile (B). The column was equilibrated before each run for 10 min in 95% A, 5% B. The flow rate and temperature were maintained at 0.2 ml/min and 25°C, respectively. IL-27 standards and un-encapsulated IL-27 were diluted into PBS, and 20 μl of each were injected onto the column. The following gradient method was used to elute IL-27: 0 to 5 min, 5 to 20% B; 5 to 50 min, 20 to 65% B; 50 to 55 min, 65 to 95% B; 55 to 60 min, 90 to 5% B. The concentration range of the IL-27 standards and that from the un-encapsulated IL-27 was chosen such that the amounts analyzed were in the linear range of the detector response for these analytes. The amount of IL-27 in the aqueous phase was subtracted from the total amount of IL-27 added to the liposomal preparation. The entrapment efficiency was then calculated from the weight of IL-27 encapsulated in liposomes as a percentage of the total weight of IL-27 added.
Stability of liposomes
The stability of liposomes was assessed by measuring their size and polydispersity index (PDI) at different time points after preparation. Liposomes containing FITC were stored at room temperature, and their size and PDI were measured on d 0, d 10 and d 50. However, considering the fragility of entrapped IL-27, the stability testing of IL-27-liposomes was limited to 7 days. These liposomes were stored at 4°C and the size and PDI measured on d 0 and d 7.
In-vitro binding of liposomes to endothelial cells
Human umbilical vein endothelial cell (HUVEC) line was obtained from the ATCC (American Type Culture Collection, Manassas, VA, USA). HUVEC were grown in endothelial cell basal medium (EGM-2 BulletKit (CC-3156 & CC-4176), Lonza, USA) containing 10% fetal bovine serum. Cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. The binding of FITC-liposomes to HUVEC was determined qualitatively by using a flow cytometer (BD FACS CANTO II). HUVEC were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 18-24 h, cells were stained with ART-1-FITC liposomes or control-FITC liposomes at different concentrations (0.1, 0.25 μM, 0.5 μM and 1 μM) for two hours. After washing with PBS, cells were fixed with 1% paraformaldehyde for 15 min, and analyzed using a flow cytometer (BD FACS CANTO II). The same procedure was used for the time kinetic study except that HUVEC were stained with ART-1-FITC or control-FITC liposomes at 0.25 μM concentration for different time points (5 min, 30 min, 1 h, 2 h and 4 h). The results were analyzed using FCS express 6 flow cytometry software (De Novo Software, CA, USA).
Animals
Lewis (LEW/SsNHsd) rats were purchased from Envigo (Indianapolis, IN). Five to 6 weeks old male rats were used in this study. The rats were housed in the vivarium of the University of Maryland School of Medicine. Animals had free access to water and food, and were maintained on a 12 h light-12 h dark cycle at room temperature of 21-23°C. The handling of rats and experimental procedures performed on them in this study were done after due approval from the Institutional Animal Care and Use Committee (IACUC) for compliance with the National Institutes of Health for use of laboratory animals. Additional experimental details using these animals are provided below.
Induction and evaluation of adjuvant arthritis in rats
Lewis rats were immunized subcutaneously (s.c.) at the base of the tail with 1.5 mg/rat of heat-killed Mycobacterium tuberculosis H 37 R a (Mtb) (Difco, Detroit, MI) suspended in mineral oil as described elsewhere [24, 28] . Thereafter, the rats were observed regularly and graded for the severity of arthritis on the basis of erythema and swelling of the paws on a scale of 0-4 per paw as follows: 0 = no erythema or swelling, 1 = slight erythema or swelling of the ankle or wrist, 2 = moderate erythema and swelling at the wrist or ankle, 3 = moderate erythema and swelling at the wrist/ metacarpals or ankle/metatarsals, 4 = severe erythema and swelling of the forepaw or hind paw. At the conclusion of experiments, the hind paws of rats were harvested. These paws were decalcified by incubation in a fixative-cum-decalcifier (Cal-Ex II) solution for 2 weeks at room temperature, followed by embedding in paraffin. Thin sections (5 μm) of the paws were cut and stained with hematoxylin-eosin (H&E) for the assessment of pannus formation, cartilage damage, and bone erosion [34] [35] [36] .
In-vivo distribution of liposomes in naïve and arthritic rats
The bio-distribution of liposomes was studied using Cy7-labeled liposomes. Naïve or arthritic rats were injected intravenously with ART-1-Cy7 liposomes or control-Cy7 liposomes (200 μM) of comparable fluorescence intensity, and then subjected to real-time fluorescence imaging at 0, 2, 4 and 6 h post-injection using the IVIS® Spectrum system (PerkinElmer). After 6 h time point, rats were euthanized and their organs including the liver, heart, lung, spleen, kidney and paws were collected and examined by fluorescence imaging using the same equipment [37] .
Treatment of arthritic rats with liposomal/free IL-27
A cohort of Mtb-immunized Lewis rats was observed until the onset of arthritis. Thereafter, following randomization, these rats were separated into 5 subgroups (n = 5-7 per group). These groups of rats received intravenously (i.v.) 200 μl/rat on d 10 and 12 after disease induction one of the following: ART-1-IL-27 liposomes, control-IL-27 liposomes lacking ART-1, ART-1-displying liposomes lacking IL-27, or free IL-27. On the basis of entrapment efficiency of IL-27 in liposomes, the dose of IL-27 was 0.83 μg/injection/rat. The arthritic control group received equal volume of PBS (vehicle) i.v. All rats were then observed regularly and the severity of arthritis was assessed as described above. At the conclusion of the experiment, hind paws of rats were harvested and processed for histological examination.
Serum chemistry analysis to assess the systemic exposure profiles of various treatment modalities
The relative profiles of the effects on other organs of various treatment modalities were evaluated in the same therapeutic efficacy study described above. Blood samples were drawn from the 5 groups of rats (n = 4-5 per group) on d 25 after Mtb immunization and the sera prepared from them was analyzed for serum chemistry (Charles River, MA). Specifically, hepatic function was assessed by measuring serum levels of aspartate aminotransferase (AST), alanine transaminase (ALT), total bilirubin (TBIL), whereas renal function was assessed by measuring blood urea nitrogen (BUN), creatinine, and BUN/Creatinine ratio. Furthermore, acute/chronic tissue damage was assessed by measuring lactate dehydrogenase (LDH).
Statistical analysis
Results were analyzed and graphed using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA) and reported as standard error of the mean (SEM). Comparisons among multiple groups were assessed for significance using analysis of variance (ANOVA) and Wilcoxon ranksum test, as applicable to the data. The threshold of significance was set at P < .05.
Results
Physical characteristics and stability of liposomes
The molar ratio of ART-1-lipopeptide, DOPC, DOPE, cholesterol, and DSPE-(PEG) 45 -NH 2 of 1:1:0.5:0.5:0.01 was found to be optimal for liposomal encapsulation of FITC/Cy7/IL-27 by ART-1-displaying liposomes; the control liposomes had a similar composition except for the ART-1 peptide. The size of these liposomes was within the range of 53-165 nm, with the liposomes containing FITC (53-101 nm) or Cy7 (66-135 nm) being slightly smaller (Fig. S2, S3) than the IL-27-containing liposomes (93-165 nm) (Fig. 1C, D) . The morphology and size of the liposomes was further assessed by TEM imaging (Fig. 1A, B) , whereas their charge was measured by zeta sizer (Fig. 1E, F) . The entrapment efficiency for FITC/Cy7 was found to be almost 100% in both ART-1-displaying liposomes and control liposomes, whereas that for IL-27 ranged from 38 to 41% in these two types of liposomes. The liposomes containing FITC were stable at room temperature for 50 days (Fig. S2) , whereas those containing IL-27 were stable at 4°C for at least one week of the testing period (Fig. 1G, H) . The testing of IL-27 was done at 4°C and limited to one week owing to fragile nature of the cytokines in general.
Fig. 1. Characterization of ART-1-IL-27-liposomes (A, C, E) and control-IL-27 liposomes (B, D, F): TEM images (A, B) (− bar is 100 nm)
, and measurements of zeta size (C, D) and zeta potential (E, F), are shown. Also tested was the stability of these liposomes by measuring and comparing zeta size (G) and PDI (H) day 0 and day 7.
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ART-1-displying liposomes show higher binding to endothelial cells than control liposomes lacking ART-1
We previously reported [24] that peptide ART-1 (= ADK) showed binding to endothelial cells derived from the joints of arthritic rats as well as activated HUVEC; cultured HUVEC resemble angiogenic, activated endothelial cells, particularly when they are in active growth phase [38] . However, in this study, we used ART-1-lipopeptide for liposome preparation. To determine whether the endothelial cell-binding property of peptide ART-1 might have been affected following either its conjugation with a lipid (ART-1-lipopeptide) or its subsequent incorporation into liposomes, we tested and compared the endothelial cell binding of the ART-1-FITC liposomes and control-FITC liposomes at different concentrations as well as at each of the time points (5 min-4 h) tested (Fig. 2). 
Systemically administered ART-1-displaying liposomes preferentially home to arthritic joints
Following intravenous (i.v.) injection, ART-1-Cy7 liposomes showed significantly higher fluorescence intensity in the inflamed hind paw joints than control-Cy7 liposomes (Fig. 3A, B) .
With ART-1-Cy7 liposomes, a fluorescence signal was detected in inflamed joints as early as 2 min after i.v. injection. At 4 h time point, ART-1-Cy7 liposomes showed higher fluorescence intensity than control-Cy7 liposomes in arthritic joints. At 6 h, ex vivo imaging of different organs harvested from these rats showed fluorescence signal in the liver and inflamed joints (Fig. 3C) . In contrast, no fluorescence signal was detectable in the hind paws of naïve rats at any of the time points tested under the same conditions. We suggest that signal from the liver might be owing to clearance of Cy7 by that organ. A similar finding of fluorescence in the liver has been reported by other investigators during in vivo imaging of tumors in mice [39] . Thus, we conclude that the ART-1-Cy7 liposomes preferentially homed to inflamed joints.
Targeted delivery of liposomal IL-27 effectively suppressed the disease in arthritic rats
We observed that rats treated with IL-27 delivered via ART-1-IL-27 liposomes showed significantly reduced severity of AA compared to the vehicle-treated, control arthritic rats (Fig. 4A-C) . The difference in arthritic scores of these two groups of rats was statistically significant. However, under similar conditions, the same dose of IL-27 but delivered via liposomes lacking any surface-conjugated ART-1 (control-IL-27 liposomes) failed to inhibit the progression of AA to the same extent as the ART-1-IL-27 liposomes; instead, the severity of arthritis in the control-IL-27 liposome group was comparable to that of the vehicletreated group. The difference in arthritic scores in different groups of rats was further reinforced by histological evaluation of pannus formation, cartilage damage, and bone erosion (Fig. 4C) . These results clearly demonstrate that the display of ART-1 on liposomal surface had a profound effect on the outcome of treatment with IL-27. We next compared the relative efficacy of IL-27 delivered via ART-1-IL-27 liposomes with that of free IL-27. In this case, the liposomal delivery of IL-27 had a much higher suppressive effect on AA than the free IL-27, and the difference in arthritic scores of these two groups of rats was statistically significant.
Targeted liposomal delivery of IL-27 is effective in reducing the systemic exposure to the cytokine
The sera of rats subjected to different treatment modalities described above were tested for various analytes (Fig. 5) indicative of hepatobiliary effects (ALT, AST, and TBIL), renal effects (BUN, creatinine, and their ratio), and acute/chronic tissue damage (LDH), as elaborated under methods. Untreated arthritic rats served as a control for other treatment groups. The results are shown in Fig. 5 . Sera of rats treated with free IL-27 or control-IL-27 liposomes showed comparable levels of enzymes tested for hepatobiliary (Fig. 5A ) and tissue toxic effects (Fig. 5B) , and these enzyme levels were significantly higher than those of the ART-1-IL-27 liposome group. The latter group was comparable to the untreated arthritic controls and rats treated with ART-1 liposomes lacking IL-27 (ART-1 liposomes) in this regard. However, for renal effects (Fig. 5C.) , serum chemistry profiles of various test groups were similar to that of control rats. These results demonstrate that the adverse effects of IL-27 therapy were significantly reduced when the same cytokine was delivered via targeted therapy using ART-1-IL-27 liposomes in comparison to free IL-27 or control-IL-27 liposomes.
Taking together results of efficacy assessment of arthritis severity (Fig. 4) and serum chemistry for systemic exposure evaluation (Fig. 5) , we conclude that ART-1-mediated targeted delivery significantly improved the therapeutic index of IL-27 compared with other modalities of treatment tested.
Discussion
The therapeutic index of currently available drugs for RA is compromised by adverse reactions that accompany the prolonged use of these drugs and/or their mode of action. This is attributable in part to the unwanted exposure of other organs besides the joints to the drugs which are given orally or by systemic injection. We hypothesized that it might be possible to circumvent the side effect problem by targeting a systemically administered drug into inflamed joints, so that majority of the drug reaches the arthritic joints, and the dose administered could be reduced. Specifically, the goal of our targeted drug delivery approach was to enhance the therapeutic index of IL-27 compared to the conventional delivery approach. In this proof-of-concept study, we exploited 3 components: a novel ligand, peptide ART-1; a relatively new immunomodulatory cytokine, IL-27; and a well-studied drug delivery vehicle, liposome. Overall, the size of different types of liposomes is within expected range. Although the net charge on ART-1-IL-27 liposomes was different from that of control liposomes, we attribute that primarily to the inclusion of the peptide in the liposomal membrane. However, for therapy, equivalent amount of cytokine (per Kg body weight) was given to rats, therefore, all rat groups received equal amount of IL-27. Our results show that the peptide-targeted liposomal delivery of IL-27 is more effective than free IL-27 in controlling arthritis.
Previous studies by other investigators have reported on the use of liposomal drug delivery (e.g., methotrexate, dexamethasone and prednisolone, etc.) for arthritis therapy in AA as well as in a collagen-induced arthritis model [40] [41] [42] [43] . However, most of these studies were based on plain liposome formulations that lacked a surface ligand to direct the liposomes to the inflamed joints. Three studies using peptide ligands for drug delivery have been reported in the AA model [19] [20] [21] . Koning et al. entrapped dexamethasone in the PEGylated, RGD-conjugated liposomes for drug delivery into inflamed arthritic joints [19] . Vanniasinghe et al. conjugated a targeting peptide for fibroblast-like synoviocytes onto the surface of prednisolone-carrying liposomes [20] . In a recent study, Poh et al. used folate-conjugated, betamethasonecontaining liposomes to image and treat arthritis [21] . Liposomal drug delivery systems have also been used in other autoimmune diseases. Liposomes were used for infliximab delivery to the eyes in the rat model of experimental autoimmune uveoretinitis [44] and methylprednisolone hemisuccinate used in an experimental autoimmune encephalomyelitis (EAE) model of human multiple sclerosis [45] . Furthermore, liposomes displaying a peptide [46] , an antibody (e.g., anti-α8 integrin or anti-CD4 antibody) [23, 47] , or glutathione [48] have been employed for drug delivery in other autoimmune diseases including EAE, lupus, and other glomerular diseases. These studies, along with that mentioned below [49] , reveal the rapid expansion of the targeted drug delivery approaches to the field of autoimmunity. The present study on arthritis describes a liposomal drug delivery system with a targeting ligand (ART-1) and therapeutic agent (IL-27) that have not been previously used in nanoparticle-based arthritis therapy.
Three main considerations in developing targeted liposomal delivery of IL-27 into inflamed joints were that-a) the ART-1 peptide displayed on the surface of liposomes retained its binding activity to activated endothelial cells; b) IL-27 retained its biological activity in the liposomal entrapment procedure; and c) the therapeutic index of IL-27 delivered via ART-1-displaying liposomes was superior to that of free IL-27, implying higher efficacy and reduced systemic adverse effects. Our results show that all these 3 conditions were met by our experimental system. For example, ART-1-FITC liposomes displayed much higher binding to HUVEC than control-FITC liposomes, showing the binding efficacy of the ART-1-coating of the liposomes. Similarly, liposomal IL-27 induced a comparable (when using control-IL-27 liposome) or higher (when using ART-1-IL-27 liposome) suppressive effect on AA compared to free IL-27, demonstrating that the bioactivity of IL-27 was maintained in the process of liposomal encapsulation. Furthermore, ART-1-directed liposomal IL-27 had higher efficacy than undirected (control) liposomal IL-27 or free IL-27. Finally, in regard to the systemic exposure profile, ART-1-IL-27 liposome group showed significantly reduced adverse effects compared with free IL-27, thus enhancing the therapeutic index of IL-27 therapy.
IL-27 has been shown to possess both pro-and anti-inflammatory properties depending on the type of disease (infectious, autoimmune) and local biological milieu at the site of inflammation, including the presence of other cytokines and mediators of inflammation. However, increasing evidence from studies in autoimmune disease models favors the immunoregulatory effects of IL-27 in arthritis, EAE, and some other autoimmune diseases [25, 27] . In our previous study, we showed that the treatment of arthritic rats with free IL-27, injected intraperitoneally, suppressed AA [28] . Similarly, other investigators have shown that the induction of IL-27 expression in the synovial tissue inhibits arthritis progression in mice with collagen-induced arthritis [29] . IL-27 inhibits Th17 differentiation and IL-17 response, but increases Th1 differentiation and IFN-ɣ response. Apparently, the increased IFN-ɣ also contributes to the inhibition of IL-17 response. In addition, we have previously shown that IFN-ɣ can induce IL-27 in vitro. Taken together, these observations suggest that IFN-ɣ and IL-27 may cooperate during the course of AA to downregulate the pathogenic Th17/IL-17 response. IL-27 also modulates other processes associated with inflammation and tissue damage, such as angiogenesis, osteoclastogenesis, and matrix degradation, and has also been found to be effective in the treatment of autoimmune diseases other than arthritis [25] . For example, s.c. injection of IL-27 has been shown to suppress EAE induction [50] . Similarly, oral delivery of genetically-engineered, IL-27-expressing Lactococcus lactis suppressed enterocolitis [51] .
Significant effort has been invested over the past few decades to the development of anti-cytokine/ cytokine receptor agents (e.g., anti-TNFα or anti-IL-6R antibodies) for RA therapy, and these advances has revolutionized RA therapy [52] . This effort can be further complemented by employing certain immunomodulatory cytokines per se as drugs, as exemplified by the use of IL-27 for arthritis therapy in our previous study in AA [28] and targeted therapy with IL-4 using a conjugate of the cytokine with a synovial endothelium-targeting peptide CKSTHDRLC in the synovial xenograft model of RA [49] . The latter study elaborated the advantages of the IL-4-peptide conjugate compared with IL-4 alone. However, because of the inherent difference in the amount of cytokine that can potentially be delivered in the form of a peptide-cytokine conjugate versus cytokine entrapped in a peptide-directed nanoparticle, the relative comparison of these two approaches remains to be assessed for different peptide ligands mentioned above 
